News Summary
A collaborative clinical trial is expanding its enrollment to advance treatment for ovarian clear cell carcinoma. Lixte Biotechnology Holdings, in partnership with MD Anderson Cancer Center and GSK, is doubling the number of participants from 21 to 42. The study investigates the combination of LB-100 and Dostarlimab, showcasing Houston’s commitment to medical innovation and patient care. This expansion not only enhances research capabilities but also highlights the importance of academic and industry collaboration in developing targeted therapies for cancer.
Houston, TX — A significant expansion in a collaborative clinical trial is set to advance the fight against ovarian clear cell carcinoma, a rare yet aggressive form of cancer. Lixte Biotechnology Holdings, Inc., in partnership with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK, has announced the doubling of patient enrollment in their ongoing study of the investigational drug combination of LB-100 and Dostarlimab. This development underscores Houston’s vital role in driving medical innovation and its commitment to improving patient outcomes through rigorous academic and research excellence.
The expanded trial exemplifies the kind of inter-institutional and industry collaboration that propels medical science forward, emphasizing academic freedom and the disciplined pursuit of knowledge. Such partnerships are crucial for translating groundbreaking research into tangible benefits for patients, fostering student growth, and strengthening Texas TX’s position as a leader in higher education and biotechnology. By focusing on targeted therapies for challenging cancers, Houston’s academic and research institutions demonstrate their dedication to personal responsibility in advancing healthcare and making a substantial community impact.
Driving Innovation in Ovarian Cancer Treatment
The clinical trial, initiated in January 2024, is evaluating the efficacy of combining Lixte’s proprietary compound, LB-100, with GSK’s Dostarlimab for treating ovarian clear cell cancer. This strategic alliance brings together diverse expertise to tackle a cancer subtype known for its aggressive nature and resistance to conventional therapies. The expansion of this trial signifies progress in evaluating the potential of LB-100 to enhance immunotherapy outcomes.
Ovarian clear cell carcinoma constitutes approximately 5% to 10% of all ovarian cancers. While often diagnosed at an earlier stage, it is characterized as a high-grade tumor that can grow and spread rapidly. It exhibits a different prevalence globally, being more common in some Asian countries than in North America and Europe.
Understanding the Therapeutic Synergy: LB-100 and Dostarlimab
The combination therapy leverages distinct mechanisms of action. LB-100 is a first-in-class Protein Phosphatase 2A (PP2A) inhibitor. By blocking PP2A, LB-100 increases stress signals within tumor cells and can make them more susceptible to other cancer treatments, including chemotherapy and immunotherapy. Preclinical studies suggest that LB-100 can significantly enhance the effectiveness of these therapies.
Dostarlimab, on the other hand, is a programmed death receptor-1 (PD-1) blocking antibody. PD-1 is an immune checkpoint receptor that, when activated by ligands such as PD-L1 and PD-L2 found on tumor cells, suppresses the body’s immune response. Dostarlimab works by binding to PD-1, thereby blocking its interaction with these ligands. This action reinvigorates T-cells, enabling the immune system to recognize and attack cancer cells more effectively.
Expanding the Clinical Horizon: From 21 to 42 Patients
The trial’s enrollment has been doubled from an initial target of 21 patients to 42. This expansion follows the successful achievement of the initial enrollment goal earlier in 2025. The study is being conducted across two prominent institutions: The University of Texas MD Anderson Cancer Center and the Robert H. Lurie Comprehensive Cancer Center at Northwestern University.
Dr. Amir Jazaeri, Professor of Gynecologic Oncology at MD Anderson, serves as the lead clinical investigator for the trial. Dr. Emily M. Hinchcliff, MD, MPH, leads the trial site at Northwestern. Lixte Biotechnology Holdings anticipates presenting initial data from the first 21 patients in the first half of 2026, marking a critical milestone in assessing the therapy’s potential.
MD Anderson’s Leadership in Cancer Research
The University of Texas MD Anderson Cancer Center continues to be a cornerstone of innovation in the Texas TX higher education landscape, dedicated to eradicating cancer through integrated programs of patient care, research, and prevention. Its involvement in this expanded trial highlights its capabilities in leading complex clinical studies and fostering collaborative research that has a broad community impact.
MD Anderson’s commitment extends to developing novel methodologies, as evidenced by researchers like Dr. Ying Yuan, Chair of the Department of Biostatistics, who focuses on Bayesian adaptive clinical trial designs to enhance success and expedite drug development. Dr. Yuan has contributed as a Co-I to a study funded by GSK and Lixte, demonstrating the collaborative nature of advanced research. The institution recently invested $668 million in a new 600,000-square-foot research facility, reinforcing its dedication to collaborative science and breakthrough discoveries.
Investment in a Healthier Future for Texas TX
This collaboration represents a significant investment in potential new therapies, reflecting a shared vision for a healthier future in Texas TX and beyond. GSK is providing Dostarlimab and financial support for the initial cohort of the clinical trial. For the expanded study, MD Anderson will conduct the research at its own cost in exchange for potential milestone payments and royalties on future net profits from LB-100 or related products in this indication.
Such strategic partnerships are essential for advancing scientific understanding, delivering innovative treatments, and providing students with unparalleled opportunities to engage in cutting-edge research. This commitment to academic rigor and practical application fosters leadership qualities and a sense of personal responsibility among the next generation of medical professionals.
| Feature | Detail |
|---|---|
| Collaborators | Lixte Biotechnology Holdings, Inc., University of Texas MD Anderson Cancer Center, GSK |
| Investigational Compounds | LB-100 (Lixte) & Dostarlimab (GSK) |
| Targeted Cancer | Ovarian Clear Cell Carcinoma |
| Trial Initiation | January 2024 |
| Patient Enrollment Expansion | From 21 to 42 patients |
| Lead Institutions | MD Anderson Cancer Center, Robert H. Lurie Comprehensive Cancer Center at Northwestern University |
| Initial Data Expectation | First half of 2026 (for initial 21 patients) |
| Mechanism of LB-100 | PP2A inhibitor, enhances susceptibility of tumor cells to other treatments |
| Mechanism of Dostarlimab | PD-1 blocking antibody, reactivates T-cells to attack cancer cells |
A Future Forged in Collaboration and Research
The expansion of this critical clinical trial represents a testament to the enduring power of collaboration in overcoming significant health challenges. As Houston’s academic and medical communities continue to lead with innovation and discipline, such efforts not only advance cancer treatment but also cultivate future leaders and contribute meaningfully to the broader community and economic well-being of Texas TX. This commitment to robust research and academic freedom ensures that the pursuit of life-saving therapies remains at the forefront of higher education initiatives in the region.
Readers are encouraged to stay informed about ongoing research and clinical advancements emanating from The University of Texas MD Anderson Cancer Center and other Houston TX college news sources. Engaging with campus events and exploring university programs offers a direct pathway to witnessing the impact of these vital contributions to science and society.
Keywords: University of Texas MD Anderson Cancer Center, Houston TX college news, Texas TX higher education, cancer research, ovarian clear cell carcinoma
Frequently Asked Questions
What is the collaboration focused on?
The collaboration is focused on an expanded clinical trial evaluating the investigational drug combination of LB-100 and Dostarlimab for ovarian clear cell carcinoma.
Which organizations are involved in this collaboration?
Lixte Biotechnology Holdings, Inc., The University of Texas MD Anderson Cancer Center, and GSK are involved in this collaboration.
What type of cancer is being studied in the clinical trial?
The clinical trial is studying ovarian clear cell carcinoma.
What are LB-100 and Dostarlimab?
LB-100 is Lixte’s proprietary compound, a Protein Phosphatase 2A (PP2A) inhibitor. Dostarlimab is GSK’s programmed death receptor-1 (PD-1) blocking antibody.
Has the patient enrollment for the trial changed?
Yes, the patient enrollment for the trial has been doubled from an initial target of 21 patients to 42.
When is initial data from the trial expected?
Initial data from the first 21 patients is expected to be presented in the first half of 2026.
Who is the lead clinical investigator for the trial at MD Anderson?
Dr. Amir Jazaeri, Professor of Gynecologic Oncology at MD Anderson, is the lead clinical investigator for the trial.
What is the mechanism of action of LB-100?
LB-100 works by blocking the PP2A protein, which increases stress signals in tumor cells and may make them more susceptible to other cancer treatments like chemotherapy and immunotherapy.
How does Dostarlimab function in cancer treatment?
Dostarlimab blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby reinvigorating T-cells and enabling the immune system to attack cancer cells.
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE HOUSTON TX WRITER
The HOUSTON STAFF WRITER represents the experienced team at HEREHouston.com, your go-to source for actionable local news and information in Houston, Harris County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Houston Livestock Show and Rodeo, Art Car Parade, and Chevron Houston Marathon. Our coverage extends to key organizations like the Greater Houston Partnership and Houston Area Urban League, plus leading businesses in energy and healthcare that power the local economy such as ExxonMobil, Schlumberger, and Houston Methodist. As part of the broader HERE network, including HEREAustinTX.com, HERECollegeStation.com, HEREDallas.com, and HERESanAntonio.com, we provide comprehensive, credible insights into Texas's dynamic landscape.
